Bufarenogin|cas 17008-69-4|Supplied by DC Chem

Cas No.:	17008-69-4
SMILES:	C[C@]([C@@H](C(C=C1)=COC1=O)CC2)([C@H]3O)[C@]2([C@@](CC[C@@]4([H])[C@@]5(CC[C@H](O)C4)C)([H])[C@]5([H])C3=O)O
Formula:	C₂₄H₃₂O₇
M.Wt:	416.51
Purity:	>98%, Standard References Grade
Sotrage:	4°C for 1 year, -20°C for more than 2 years

Description:

For the detailed information of Bufarenogin, the solubility of Bufarenogin in water, the solubility of Bufarenogin in DMSO, the solubility of Bufarenogin in PBS buffer, the animal experiment（test） (test) of Bufarenogin, the cell expriment (test) of Bufarenogin, the in vivo, in vitro and clinical trial test of Bufarenogin, the EC50, IC50,and Affinity of Bufarenogin,, please contact DC Chemicals.

MSDS

COA

LOT NO.	DOWNLOAD

2018-0101

Cat. No.	Product name	Field of application
DCC-003	Vincristine	>98%,Standard References
DCZ-289	songorine	purity >98%,Standard References
DCZ-286	8-GERANOPSORALEN	purity >98%,Standard References
DCZ-290	Isobavachin	purity >98%,Standard References
DCZ-292	TECTOCHRYSIN	purity >98%,Standard References
DCZ-291	isorhapontigenin	purity >98%,Standard References
DCZ-287	Protopine	purity >98%,Standard References
DC8874	7-TACA	Impurity D of Cefoperazone
DCQ-033	fraxin	Fraxin is a coumarin glycoside that has been found in Fraxinus and has anti-inflammatory activity.
DC23085	Dihydrocapsaicin	Dihydrocapsaicin, a potential inducer of autophagy, has cytotoxic activity. It has anti-atherogenic activity, can reduce the susceptibility of low-density lipoprotein (LDL) to oxidation. Dihydrocapsaicin treatment depletes peptidergic nerve fibers of subs